Novartis signals growing ambitions for cancer therapies
Drugmaker is planning to test its CAR-T treatments on lethal cancers of the brain, pancreas, colon, ovary and lung
Add BT as a preferred source
London
NOVARTIS AG is pushing ahead with one of its most ambitious cancer therapies, a treatment that the Swiss drugmaker says has blockbuster potential as it extends that technology to a wider pool of tumour-ridden patients.
Europe's second-biggest drugmaker is planning to test its CAR-T treatments - which involve extracting immune cells and genetically engineering them to hunt and kill cancer cells before returning them into the patient's body - on lethal cancers of the brain, pancreas, colon, ovary and lung. The company has also doubled its investment in manufacturing for these treatments.
TRENDING NOW
Abandoned ‘Titanic’, failing ‘ancient towns’: Why China’s tourism boom leaves white elephants behind
Private equity giant Carlyle can grow bigger but needs to stay on its toes: co-founder David Rubenstein
Singapore to establish over-the-counter gold clearing system, central bank vaulting by end-2026
Singapore public sector commands highest AI salary premium as job postings surge: PwC study
